- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07944677
Metabolism And Diet for Improving Kidney Cancer Health (MACH3) (MACH3)
The purpose of this study is to test whether a Mediterranean-style diet and a time-restricted eating plan ("intermittent fasting") are easy to follow and acceptable for people who were recently diagnosed with kidney cancer.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Tracy Crane, PhD
- Telefonnummer: (305) 243-8255
- E-mail: tecrane@miami.edu
Undersøgelse Kontakt Backup
- Navn: Jamie Merchan, MD
- Telefonnummer: (305) 243-1287
- E-mail: jmerchan2@med.miami.edu
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 18 years of age or older
- Speak and understand English or Spanish
- New diagnosis of clear cell renal cell carcinoma (RCC) who will undergo treatment with immunotherapy or immunotherapy-based combination treatments in the following two settings at the discretion of the treating investigator:
- Post-operative adjuvant
- First-line metastatic setting
Immunotherapy treatments may include:
- Pembrolizumab (adjuvant)
- Ipilimumab/nivolumab (metastatic)
- Pembrolizumab/Lenvatinib (metastatic)
- Pembrolizumab/axitinib (metastatic)
- Nivolumab/carbozantinib (metastatic)
- Approval from medical oncologist to participate
- No medical contraindications to immunotherapy or TKI therapy based on the treating physician's judgement
Exclusion Criteria:
-
Already consistently following Mediterranean or time-restricted eating ("intermittent fasting") eating pattern in the past 3 months
- Not equal to or more than 50% of the time) engaged in structured fasting (i.e., not regularly fasting for ≥12hr/night)
- Not equal to or more than 50% of the time consuming >5 servings of fruits/vegetables per day, 2 servings of fatty fish per week, 3 servings nuts/seeds per week, and using olive oil as the primary dietary oil/fat
-
Insulin-dependent diabetes or current use of glipizide
-
Uncontrolled medical conditions (including dialysis, hypertension, cardiac disease)
-
Oxygen dependence
-
Eastern Cooperative Oncology Group (ECOG) Performance status >3
-
Life expectancy <12 months
-
Estimated Glomerular Filtration Rate (EGFR) <40 mLs/min
-
History of autoimmune disorders, or contraindications to immunotherapy
-
Active, untreated CNS metastases (brain mets)
-
Psychiatric history of mental state which would negatively impact participation and adherence to the intervention, e.g. major psychiatric disease, clinical eating disorder
-
BMI <20 kg/m2
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Arm 1: Intervention (MED+FAST)
All intervention participants will receive the MED+FAST intervention, which combines time-restricted eating and a Mediterranean diet. |
All participants will receive weekly health coaching sessions during the intervention via telephone, video call, or in-person, as feasible. The health coach will contact the participant after randomization to begin the intervention, which will include education on intermittent fasting and following a Mediterranean diet. Sessions are expected to last approximately 30-45 minutes and can be divided per participant preference. The intervention is designed to support participants in adopting timerestricted eating as part of their daily dietary routine. This approach is intended to modify the timing of food intake rather than reduce overall caloric intake, with participants encouraged to maintain their usual caloric intake within the prescribed eating window. Participants will be instructed to not consume any calorie-containing food/drinks after 8pm, or when their fasting window is scheduled per patient preference, and to wait 12-14 hours after the fasting start before resuming eating the next day. The intervention also aims to support participants in adopting key components of the Mediterranean diet alongside their time-restricted eating goals. In addition to meeting time-restricted eating goals, weekly coaching sessions will encourage participants to adopt key components of a Mediterranean diet. To enhance adherence and engagement, participants in the intervention arm will receive multiple forms of support to help them successfully implement time-restricted eating and Mediterranean diet goals |
|
Ingen indgriben: Arm 2: Waitlist Control with Usual Care
Participants randomized to the usual care arm will receive standard care with remote digital biomarker monitoring. Control participants will have the option to meet with the study health coach at the end of the 12-week study and will be directed to cancer survivorship services offered at Sylvester for additional support if requested. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Feasibility of Recruitment: Percentage of Participants That Consent to Participate and Meet Eligibility Criteria
Tidsramme: Baseline
|
Feasibility of recruitment will reported as the percentage of participants who agree to participate (≥50%) at baseline. |
Baseline
|
|
Feasibility of Retention and Adherence: Percentage of Participants Who Adhere to and Complete the Intervention and Data Collection at All Time Points.
Tidsramme: Up to 12 weeks
|
Feasibility of retention and adherence will be reported as the percentage of intervention sessions completed (≥70%) at 12 weeks as measured by documented attendance/engagement each week with coach. |
Up to 12 weeks
|
|
Acceptability: Percentage of Participants Who Report Satisfaction with the Intervention
Tidsramme: Up to 12 weeks
|
Acceptability will be reported as the percentage of participants in the intervention arm of the study who report satisfaction with intervention (≥80%) at 12 weeks post-intervention as measured by 21-item participant satisfaction questionnaire, scores range from 0-5 with higher scores indicating greater satisfaction. |
Up to 12 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Response Rate (ORR)
Tidsramme: Up to 12 weeks
|
Overall Response Rate (ORR) is the proportion of patients achieving complete response (CR) or partial response (PR) as the best response. ORR will be calculated as the proportion of participants achieving a complete or partial response at 12 weeks. |
Up to 12 weeks
|
|
Number of Participants Experiencing Adverse Events (AEs)
Tidsramme: Up to 12 weeks
|
Adverse events will be assessed using patient-reported and clinician-reported measures. The number of participants experiencing adverse events will be measured. |
Up to 12 weeks
|
|
Change in Physical Function (Handgrip Strength)
Tidsramme: Baseline, up to 12 weeks
|
Change in physical function (handgrip strength) will be assessed using a hand dynamometer. Percentage change in handgrip strength will be reported at baseline, 6 weeks, and 12 weeks by study arm. |
Baseline, up to 12 weeks
|
|
Change in Diet As Assessed by the Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)
Tidsramme: Baseline, up to 12 weeks
|
Patient-reported outcomes for change in diet (ASA24) will be evaluated using the Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool. This assessment will generate a score derived from the Healthy Eating Index (HEI). HEI scores range from 0 to 100, where higher numbers reflect better overall diet quality. |
Baseline, up to 12 weeks
|
|
Change in Physical Activity As Measured By Scores on the Godin Leisure Time Exercise Questionnaire
Tidsramme: Baseline, up to 12 weeks
|
Change in participant quality of life in both the intervention and control groups as measured by the Godin Leisure Time Exercise Questionnaire will be reported. The Godin Leisure Time Exercise Questionnaire assesses participants' frequency of leisure activity/exercise (strenuous, moderate or light) for more than 15 minutes during a 7-day period. Higher scores (≥24) indicate a more active lifestyle and lower scores (≤23) indicate an insufficiently active lifestyle. Scores collected at baseline (T1) will be compared to scores collected 6 weeks (T2) and week 12 (T3). |
Baseline, up to 12 weeks
|
|
Change in Quality of Life As Measured By Scores on the PROMIS-29 Questionnaire
Tidsramme: Baseline, up to 12 weeks
|
Change in participant quality of life in both the intervention and control groups as measured by scores on the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) questionnaire will be reported. PROMIS-29 questionnaire is a 29-item validated measure using a single 0-10 numeric rating item with seven domains of health, including physical function, anxiety, depression, pain interference, fatigue, sleep disturbance, ability to participate in social roles and activities and pain intensity. Scores collected at baseline (T1) will be compared to scores collected at 6 weeks (T2) and 12 weeks (T3). Higher scores represent worse symptoms for symptom-oriented domains (anxiety, depression, fatigue, pain intensity, pain interference, and sleep disturbance) and better health outcomes for function-oriented domains (physical functioning and ability to participate in social roles and activities). |
Baseline, up to 12 weeks
|
|
Change in Sleep Quality as Assessed by the Pittsburgh Sleep Quality Index
Tidsramme: Baseline, up to 12 weeks
|
Patient-reported outcomes for change in sleep will be evaluated using the Pittsburgh Sleep Quality Index. The Pittsburgh Sleep Quality Index (PSQI) is a 19-item questionnaire used to measure the quality and patterns of sleep in adults. It evaluates sleep across seven component scores, which are summed to create a single global score ranging from 0 to 21 (where higher scores indicate poorer sleep quality). |
Baseline, up to 12 weeks
|
|
Change in Physical Activity as Measured By Participant Accelerometry Data, in Steps Per Day
Tidsramme: Baseline, 12 weeks
|
Participant physical activity will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3). Physical activity measures will include average daily step count in steps per day. |
Baseline, 12 weeks
|
|
Change in Physical Activity as Measured By Participant Accelerometry Data, in Minutes Per Day
Tidsramme: Baseline, 12 weeks
|
Participant physical activity will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3). Physical activity measures will include sedentary time; light-intensity physical activity (LPA); moderate-intensity physical activity (MPA); vigorous-intensity physical activity (VPA); and total physical activity all in minutes per day. |
Baseline, 12 weeks
|
|
Change in Sleep as Measured By Participant Accelerometry Data, in Minutes Per Night
Tidsramme: Baseline, 12 weeks
|
Participant sleep will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3). Sleep measures will include total sleep time; wake after sleep onset (WASO); and time in bed by minutes per night. |
Baseline, 12 weeks
|
|
Change in Sleep as Measured By Participant Percentage of Sleep Efficiency
Tidsramme: Baseline, 12 weeks
|
Participant sleep will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3). Sleep measures will include percentage of sleep efficiency. |
Baseline, 12 weeks
|
|
Change in Sleep as Measured By Participant Accelerometry Data, in Awakenings Per Night
Tidsramme: Baseline, 12 weeks
|
Participant sleep will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3). Sleep measures will include number of awakenings in awakenings per night. |
Baseline, 12 weeks
|
|
Change in Sleep as Measured By Participant Accelerometry Data, in Minutes
Tidsramme: Baseline, 12 weeks
|
Participant sleep will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3). Sleep measures will include sleep onset latency in minutes. |
Baseline, 12 weeks
|
|
Change in Anthropometrics
Tidsramme: Baseline, 12 weeks
|
Changes in anthropometric measurements will be assessed using standard-of-care abdominal CT and MRI scans. Anthropometric measures will include height in centimeters (cm); body weight in kilograms (kg); body mass index (BMI) in kilograms per meter squared (kg/m^2); waist circumference in cm; hip circumference in cm; waist-to-hip ratio (if calculated). |
Baseline, 12 weeks
|
|
Change in Body Composition
Tidsramme: Baseline, 12 weeks
|
Changes in body composition characteristics will be assessed using standard-of-care abdominal CT and MRI scans. Omron BIA measures will include percentage of total body fat; percentage of skeletal muscle; and visceral fat rating (unitless). CT-derived composition measures will include skeletal muscle cross-sectional area in cm^2; skeletal muscle index (SMI) in cm^2/m^2; visceral adipose tissue are (VAT) in cm^2; subcutaneous adipose tissue are (SAT) in cm^2; skeletal muscle radiodensity in Hounsfield units (HU); and intramuscular adipose tissue area in cm^2. |
Baseline, 12 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Tracy Crane, PhD, University of Miami
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Urologiske neoplasmer
- Karcinom
- Nyre-neoplasmer
- Karcinom, nyrecelle
- Terapeutik
- Diæt, mad og ernæring
- Fysiologiske fænomener
- Ernæringsfysiologiske fænomener
- Diæt, plantebaseret
- Diætterapi
- Ernæringsterapi
- Kost
- Diæt, Middelhavet
Andre undersøgelses-id-numre
- 20251387
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .